



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/571,184

07/17/2006

David Morton

478.1077

9629

23280 7590 03/10/2011
Davidson, Davidson & Kappel, LLC
485 7th Avenue
14th Floor
New York, NY 10018

EXAMINER

OLSON, ERIC

ART UNIT

PAPER NUMBER

1623

MAIL DATE

DELIVERY MODE

03/10/2011

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10571184	7/17/2006	MORTON ET AL.	478.1077

Davidson, Davidson & Kappel, LLC
485 7th Avenue
14th Floor
New York, NY 10018

EXAMINER

ERIC OLSON

ART UNIT	PAPER
----------	-------

1623

20110308

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Applicant's information disclosure statement, submitted February 17, 2011, and the enclosed references, have been fully considered and not found to be the basis for any new grounds of rejection against the claims as previously allowed in the notice of allowance submitted January 4, 2011.

The information disclosure statement contains two correspondences from foreign patent offices. Both documents present grounds of rejection against claims in related applications filed by the Applicant. However, neither document addresses the limitation in the previously allowed claims requiring that the composition used in the claimed method contain 2% w/w or more of leucine. As discussed in the notice of allowance submitted January 4, 2011, Applicant has disclosed that the combination of heparin and 2% or more of leucine, as required by the present claims, produces an unexpected improvement in the fine particle fraction of the composition, thereby overcoming any prima facie case of obviousness previously made in this application for adding 2% or more of leucine to such a composition. As discussed previously, because this effect is specific to the combination of heparin and leucine, references such as WO01/32144, which are generic to a large number of active agents, with no specific teaching of combining heparin and leucine, do not render the claims obvious.

/Eric S Olson/
Primary Examiner, Art Unit 1623